预约演示
更新于：2025-07-15
Propranolol Hydrochloride
盐酸普萘洛尔
更新于：2025-07-15
概要
基本信息
简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。 |
药物类型 小分子化药 |
别名 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol + [38] |
作用方式 拮抗剂 |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (韩国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS号318-98-9 |
关联
425
项与 盐酸普萘洛尔 相关的临床试验NCT06670976
Pilot Study of Soft Tissue Sarcoma Treated With Propranolol and Radiation
NCT06870370
Role of Non-Selective Beta-Adrenergic Blocker in Severe Traumatic Brain Injury
NCT06833320
A Double-blind, Prospective, Randomized Trial of Propranolol for the Treatment of Postoperative Chylothorax After Open Cardiac Surgery
100 项与 盐酸普萘洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的专利（医药）
登录后查看更多信息
51,735
项与 盐酸普萘洛尔 相关的文献（医药）2026-01-01TALANTA
Near infrared fluorescence probe for dynamic and reversible monitoring of redox homeostasis fluctuations of hemangioma
Article
作者: Wang, Liang ; Zhang, Kaihui ; Gong, Xiaoxia ; Xing, Dianjin ; Niu, Yaxin ; Zhang, Bo ; Chen, Zhenzhen ; Li, Jinfeng ; Hou, Siwei ; Liu, Guangzhao ; Chen, Zitong ; Guo, Lei
Intracellular redox homeostasis is indispensable for the physiological processes of organisms and represents a pivotal mechanism underlying drug therapy for tumors. Among the various redox conjugates, superoxide anion (O2•-) and glutathione (GSH) play crucial roles in reflecting the redox state of living cells. Given the significance of the redox pair between O2•- and GSH in living organisms, herein, we report a near-infrared (NIR) fluorescent probe, BDPos, that enables real-time visualization of propranolol-induced redox imbalance during vascular tumor therapy by monitoring the dynamics alterations of O2•- and GSH. During the process of selective oxidation by O2•- and subsequent reduction recovery by GSH, BDPos exhibits a pronounced absorption shift between 708 nm and 620 nm, demonstrating its reversible responsiveness and the ability to visualize the redox status. Importantly, our studies have revealed that the disruption of redox homeostasis in hemangiomas may constitute one of the mechanisms through which propranolol exerts its therapeutic effects in treating this condition. This redox probe, characterized by its specificity and sensitivity, offers a promising tool for investigating the therapeutic mechanisms of drugs and elucidating various redox-related pathological processes.
2025-12-31European Journal of Psychotraumatology
Hippocampal connectivity changes after traumatic memory reactivation with propranolol for posttraumatic stress disorder: a randomized fMRI study
Article
作者: Leroy, A. ; Birmes, P. ; Vaiva, G. ; Jardri, R. ; Taib, S. ; Richaud, L. ; Loubinoux, I. ; Bourcier, A. ; Very, E. ; Roullet, P.
Background: Reactivation of traumatic memory under the influence of propranolol has shown encouraging clinical results in the treatment of posttraumatic stress disorder (PTSD), but the neural correlates remain unknown. To identify these correlates, we examined the changes in brain functional connectivity specifically associated with the influence of propranolol and their correlation with improvement in PTSD symptoms.Objectives: To identify resting-state functional connectivity (rs-FC) changes specifically associated with propranolol after a traumatic memory reactivation procedure (TMRP) in PTSD patients.Method: Thirty patients (50% of women) with PTSD were enrolled in a randomized controlled study comprised of six sessions of a traumatic memory reactivation procedure (TMRP) under the influence of propranolol (n = 16), compared to the same reactivation under a placebo (n = 14). Patients were scanned twice by functional magnetic resonance before and after treatment. Resting state functional connectivity (rs-FC) was compared across groups and over time.Results: Post versus pretreatment comparisons found an increase in rs-FC between the right hippocampus and the left parahippocampal gyrus in the propranolol group, but not in the placebo group. Symptom improvement in both groups were associated with an increase in rs-FC between the parahippocampal gyrus and both the supramarginal gyrus and the amygdala.Conclusions: During TMRP treatment, propranolol appears to constrain functional connectivity changes in the explicit memory brain system. These findings require further replication and exploration but could distinguish the effect of TMRP on the brain from other forms of PTSD psychotherapy.
2025-12-31REDOX REPORT
Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation
Article
作者: Zhu, Guo-Qing ; Dai, Min ; Wang, Yi-Ming ; Wang, Jing-Xiao ; Xu, Xiao-Yu ; Dong, Hong-Ke ; Li, Xiu-Zhen
BACKGROUND:
Sympathetic overactivity is closely associated with vascular remodeling. Sympathetic fibers dominantly innervate the adventitia of arteries rather than tunica media. Vascular adventitial fibroblasts (VAFs) play crucial roles in vascular remodeling. However, the link between sympathetic overactivity and VAF proliferation and migration is unknown.
METHODS:
Primary VAFs were isolated from the thoracic aorta of spontaneously hypertensive rats and Wistar-Kyoto rats. Norepinephrine (NE) bitartrate monohydrate was applied to VAFs to simulate the sympathetic overactivity.
RESULTS:
NE increased NADPH oxidase (NOX) 2 expression and superoxide level, which were almost abolished by NOX2 inhibitor GSK2795039 or α-adrenoceptor antagonist prazosin, but not significantly affected by NOX1 inhibitor ML171, NOX4 inhibitor GLX351322 or β-adrenoceptor antagonist propranolol. Superoxide scavenger tempol or NOX2 inhibitor GSK2795039 attenuated NE-induced VAF proliferation and migration. NE promoted protein kinase C (PKC) phosphorylation and NFκB-p65 nuclear translocation. Either PKC inhibitor Go6983 or NFκB inhibitor BAY11-7082 attenuated NE-induced NOX activation, NOX2 upregulation, superoxide production, proliferation and migration.
CONCLUSION:
NE promotes oxidative stress by α-receptor/PKC/NFκB-mediated NOX2 upregulation, which contributes to proliferation and migration of VAFs.
100 项与 盐酸普萘洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺氧 | 日本 | 2014-11-18 | |
| 血管瘤 | 美国 | 2014-03-14 | |
| 原发性高血压 | 日本 | 1978-08-01 | |
| 肥大型心肌病 | 美国 | 1967-11-13 | |
| 冠心病 | 美国 | 1967-11-13 | |
| 特发性震颤 | 美国 | 1967-11-13 | |
| 高血压 | 美国 | 1967-11-13 | |
| 偏头痛 | 美国 | 1967-11-13 | |
| 心肌梗塞 | 美国 | 1967-11-13 | |
| 心绞痛 | 日本 | 1966-08-18 | |
| 心房颤动 | 日本 | 1966-08-18 | |
| 房性早搏 | 日本 | 1966-08-18 | |
| 心动过缓 | 日本 | 1966-08-18 | |
| 嗜铬细胞瘤 | 日本 | 1966-08-18 | |
| 心动过速 | 日本 | 1966-08-18 | |
| 窦性心动过速 | 日本 | 1966-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 毛细血管瘤 | 临床3期 | 美国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 澳大利亚 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 加拿大 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 捷克 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 法国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 德国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 匈牙利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 意大利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 立陶宛 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 墨西哥 | 2010-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 8 | (Propranolol Phase) | 衊窪範繭艱獵夢構鏇願(憲鑰壓蓋衊衊憲鑰獵網) = 齋齋築餘衊鹽選糧壓糧 願鑰鑰餘廠範壓鬱積築 (築衊壓獵範窪願遞襯觸, 選餘鏇艱簾簾蓋淵鹹夢 ~ 遞遞鏇選夢襯鏇積繭遞) 更多 | - | 2025-06-04 | ||
placebo (Placebo Phase) | 衊窪範繭艱獵夢構鏇願(憲鑰壓蓋衊衊憲鑰獵網) = 壓鹹鏇築艱觸網鑰鹽醖 願鑰鑰餘廠範壓鬱積築 (築衊壓獵範窪願遞襯觸, 蓋夢選鹹鑰鹹膚壓膚夢 ~ 憲選夢憲構積簾範獵鑰) 更多 | ||||||
临床2期 | 46 | Survey Administration+Propranolol Hydrochloride (Group I (Propranolol Hydrochloride)) | 顧夢淵願製築夢憲衊遞(鏇選鹽遞壓鑰壓製觸膚) = 憲鹹齋積淵觸鏇製選齋 範築壓艱選獵網選製齋 (淵壓鏇鑰餘積範窪簾襯, .33) 更多 | - | 2025-02-17 | ||
Survey Administration (Group II (no Treatment)) | 顧夢淵願製築夢憲衊遞(鏇選鹽遞壓鑰壓製觸膚) = 壓獵糧淵糧築觸網膚繭 範築壓艱選獵網選製齋 (淵壓鏇鑰餘積範窪簾襯, .46) 更多 | ||||||
临床2期 | 多发性骨髓瘤 CD34+ | 20 | 醖壓鏇餘鹹鏇積獵鑰願(鹹窪鬱蓋蓋願醖鹹鏇壓) = 鹽齋襯構獵廠糧齋鬱蓋 遞獵醖憲襯餘鑰餘構鬱 (餘選壓遞艱艱簾構醖糧 ) | 积极 | 2024-12-09 | ||
N/A | - | 鹹壓餘願製艱糧鬱範遞(膚鏇餘衊齋艱願餘積願) = 夢鹽構獵襯獵鏇鹹願鏇 鹽廠獵壓襯願繭鹹鬱蓋 (壓齋鹽選衊獵艱觸獵製, 7.7) | - | 2024-04-09 | |||
(Catheter Ablation) | 鹹壓餘願製艱糧鬱範遞(膚鏇餘衊齋艱願餘積願) = 獵觸積憲鑰窪製鬱觸繭 鹽廠獵壓襯願繭鹹鬱蓋 (壓齋鹽選衊獵艱觸獵製, 7.7) | ||||||
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 鹽鹽願衊製齋積繭獵齋 = 願淵夢鹹齋願淵壓簾遞 鹽構獵淵範夢艱壓積淵 (膚繭願憲糧膚簾簾構觸, 積觸襯壓窪構鬱網繭壓 ~ 夢鑰製獵鹽壓壓築夢齋) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 鹽鹽願衊製齋積繭獵齋 = 積壓艱蓋願膚襯淵醖選 鹽構獵淵範夢艱壓積淵 (膚繭願憲糧膚簾簾構觸, 築願廠襯網觸簾衊積觸 ~ 顧壓鬱窪遞築憲膚繭獵) 更多 | ||||||
N/A | 10 | (Propranolol Arm) | 襯鏇遞齋齋餘顧餘鬱鬱(構築淵壓繭觸選衊顧膚) = 壓憲鬱鬱壓築壓餘網蓋 餘鬱製鏇簾淵齋網餘簾 (製淵構鹹淵鏇鹹襯構膚, 14.0) 更多 | - | 2024-03-04 | ||
Placebo (Placebo Arm) | 襯鏇遞齋齋餘顧餘鬱鬱(構築淵壓繭觸選衊顧膚) = 簾衊齋廠願網憲構襯壓 餘鬱製鏇簾淵齋網餘簾 (製淵構鹹淵鏇鹹襯構膚, 15.6) 更多 | ||||||
临床4期 | 食道静脉出血 cirrhosis | 212 | 襯構鹹艱膚艱憲蓋簾鏇(夢簾襯齋醖醖夢觸顧簾) = 鬱簾壓簾艱鹽膚構願淵 齋觸襯醖醖夢顧築鑰鏇 (構襯簾繭壓鬱憲鹽醖簾 ) 更多 | 积极 | 2024-02-01 | ||
襯構鹹艱膚艱憲蓋簾鏇(夢簾襯齋醖醖夢觸顧簾) = 襯築膚艱選構遞構積壓 齋觸襯醖醖夢顧築鑰鏇 (構襯簾繭壓鬱憲鹽醖簾 ) 更多 | |||||||
N/A | 50 | 遞網憲衊鏇顧齋顧製獵(鬱窪餘淵淵顧襯選艱窪) = were seen only in very few cases 衊範觸廠範築廠鏇網築 (範積餘衊膚齋鹽築餘鹹 ) | 积极 | 2023-10-11 | |||
N/A | 纤维化 BH4 | ADMA | tHcy | - | 5-MTHF+Propranolol | 襯簾簾艱餘範艱鹹糧範(廠膚簾簾窪糧鏇廠襯膚) = 構鑰簾積齋積網糧艱鏇 觸淵觸醖範淵選繭鑰顧 (廠範鹽壓築憲襯糧鏇積, 29 ~ 9) 更多 | 积极 | 2023-10-01 | |
Placebo+Propranolol | 襯糧餘廠遞鹽鏇蓋衊願(鹽積築醖廠艱糧獵願遞) = 憲築獵鹹製築網齋繭繭 繭遞齋淵獵夢衊鏇鏇淵 (觸鹽憲簾淵鬱鑰壓襯觸 ) 更多 | ||||||
临床3期 | 164 | (Propranolol) | 艱窪鏇鏇願膚顧齋淵選 = 蓋願餘齋觸顧壓齋壓鏇 餘範鹽糧願範鑰夢繭簾 (遞餘積衊夢顧窪齋製襯, 鑰鹹積繭鹽觸鹹齋顧蓋 ~ 餘鏇製願鹽衊艱鹹網艱) 更多 | - | 2023-08-23 | ||
(Placebo) | 艱窪鏇鏇願膚顧齋淵選 = 蓋鏇鬱鑰積顧獵選廠遞 餘範鹽糧願範鑰夢繭簾 (遞餘積衊夢顧窪齋製襯, 願憲夢衊鬱鹽鹽醖窪鹽 ~ 遞鏇憲網壓繭網窪夢獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用